On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee backed six of seven peptides for the Section 503A Bulk Drug Substances List.
The 503A Bulks List is the federal list of bulk ingredients that may be used for patient-specific compounding when other legal conditions are met. The committee recommended adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. It recommended against adding Emideltide, also known as delta sleep-inducing peptide or DSIP.
For anyone checking the FDA status of BPC-157 or TB-500, the short answer is no: neither is FDA approved, and neither has been added to the federal compounding list. The same is true of the other five peptides reviewed. The committee's votes are recommendations, not final FDA decisions. The agency must still review the record and complete its rulemaking process before the list changes. As of publication, the federal regulation that contains the 503A Bulks List includes none of the seven peptides.
That is a meaningful result. It is also narrower than many headlines made it sound.
The panel's makeup is part of the story too. STAT reported that most panelists who voted yes had ties to the peptide industry. Those ties do not settle whether the recommendations were right, but they are essential context for reading the result.
The FDA Peptide Vote Results
The FDA's official voting questions asked separately about the free-base and acetate forms, two chemical versions of each ingredient. FDA has not yet posted form-by-form minutes or a transcript. The table therefore follows the substance-level tallies reported by STAT and the Associated Press.
| Peptide | Use FDA evaluated | Reported tally | Result |
|---|---|---|---|
| BPC-157 | Ulcerative colitis | 8 yes, 6 no, 1 abstention | Recommended |
| KPV | Wound healing and inflammatory conditions | 8 yes, 6 no, 1 abstention | Recommended |
| TB-500 | Wound healing | 8 yes, 6 no, 1 abstention | Recommended |
| MOTS-c | Obesity and osteoporosis | 7 yes, 5 no | Recommended |
| Epitalon | Insomnia | 7 yes, 4 no | Recommended |
| Semax | Cerebral ischemia, migraine, and trigeminal neuralgia | 8 yes, 5 no | Recommended |
| Emideltide (DSIP) | Opioid withdrawal, chronic insomnia, and narcolepsy | 6 yes, 7 no | Not recommended |
The Associated Press reported the July 23 results. STAT's July 24 recap reported that day's results and restated the July 23 tallies. The uses reviewed are from the FDA meeting record.
Every substance-level result was decided by three votes or fewer. The first three passed 8 to 6, with one abstention. MOTS-c, Epitalon, and Semax also advanced by narrow margins. Emideltide failed by one vote. The FDA roster shows that several members and temporary members were assigned only to specific peptide topics, so the eligible panel was not identical for every vote. FDA has not yet posted minutes detailing any additional absences or recusals.
What the Committee Actually Decided
The committee did not decide whether these peptides are FDA-approved drugs. It did not approve a particular product, dose, route, manufacturer, or broad set of advertised uses.
It answered a more limited question: should these bulk ingredients be eligible for use in patient-specific compounding under Section 503A?
Compounding means a licensed pharmacist or physician prepares a customized medication for an individual patient. The 503A pathway allows qualifying compounded drugs to be exempt from parts of the normal drug-approval, labeling, and manufacturing framework. The FDA's briefing document explains those exemptions and the four factors the agency weighs: chemical characterization, safety, evidence of effectiveness, and history of use.
Even a final place on the 503A Bulks List would not mean:
- The peptide is FDA-approved.
- Every claimed use is supported by clinical evidence.
- It can be sold over the counter.
- A research-use product is suitable for human use.
- Every compounded preparation has been reviewed by FDA for safety, effectiveness, or quality.
This distinction matters because "recommended for the compounding list" and "FDA approved" describe different regulatory pathways.
The Vote Did Not Change the List
The panel's favorable recommendations did not place the six peptides on the 503A Bulks List on July 23 or 24.
The FDA meeting page says advisory committees provide nonbinding advice. It notes that the agency generally follows committee recommendations but is not legally required to do so. The briefing document also says FDA would not make a final determination until it considered the committee's input and completed its reviews.
For a substance to reach the 503A Bulks List, FDA uses notice-and-comment rulemaking. In plain language, the agency publishes a proposed rule, accepts public comments, considers the record, and then issues a final rule. The FDA's 503A process page confirms that nominated substances are handled through that process.
The practical status today is therefore straightforward: six peptides have a favorable advisory recommendation, one does not, and the final federal list has not changed.
The Panel Rejected FDA's Proposal
Before the meeting, FDA proposed that neither chemical form of any of the seven peptides be included.
That position appears clearly in the agency's meeting briefing. The document proposed excluding all 14 forms, two for each of the seven substances. The committee went the other way at the substance level for six of the seven peptides.
The disagreement was not a minor technicality. FDA staff emphasized limited human evidence, uncertainty about the identity and consistency of some bulk substances, possible unwanted immune reactions, and the difficulty of controlling peptide-related impurities.
The panel's supporters focused on a different risk calculation. They argued that people are already seeking these substances and that access through licensed compounding pharmacies could be safer than purchases from unregulated sellers. Some also argued that the committee was deciding access to compounding, not granting full drug approval.
Both sides are describing a real problem. The gray market, meaning the sellers who ship these peptides today without pharmacy licensing or regulatory oversight, creates quality risks, and a regulated pharmacy is different from an anonymous online seller. Moving a substance into a less demanding regulatory pathway still does not fill the underlying gaps in dose, effectiveness, or long-term safety data.
Most Yes Votes Came From Panelists With Industry Ties
STAT's account of the meeting reported that most of the panelists voting yes had ties to the peptide industry and had been appointed by the Department of Health and Human Services. The outlet also reported that dissenting votes came largely from academic physicians and patient representatives.
The Associated Press raised the same concern before the meeting. It found that more than half a dozen people with connections to peptide clinics, pharmacies, consulting businesses, or promotion had been added to the panel. The FDA's final roster lists the members and their professional affiliations.
Industry experience can add useful context. People who prescribe or compound peptides may understand parts of patient demand, pharmacy practice, and gray-market harm that an academic researcher does not see directly. Their professional vantage point also differs from that of a patient representative or independent clinical researcher. Both belong alongside the tally, especially when the votes are this close and the committee rejects FDA's proposal across six substances.
The vote shows regulatory momentum without supplying independent scientific evidence that the six peptides are safe and effective.
The Evidence Gaps Are Still There
The FDA's current safety page remains unusually direct about what it could and could not find:
- For KPV and MOTS-c, FDA says it did not identify human exposure data for drug products using the substances by any route.
- For TB-500, FDA says it did not identify human exposure data for drug products containing this short section of the larger thymosin beta-4 protein.
- For BPC-157, FDA cites limited safety information for the proposed routes, possible unwanted immune reactions, peptide-related impurities, and uncertainty about confirming the active ingredient.
- For Semax, Epitalon, and Emideltide, FDA cites missing or limited safety information for the proposed routes and concerns about immune reactions or impurities.
An unwanted immune reaction is called immunogenicity. It can range from a product becoming ineffective to an allergic or inflammatory response. Peptides can also clump together or contain closely related byproducts that are difficult to separate and measure consistently.
A lack of evidence leaves potential harm unresolved and limits confidence until better human data exists. The committee's vote did not create that data.
What Happens Next
Three steps matter now:
- FDA reviews the full record. That includes the briefing documents, committee discussion, votes, and public comments.
- FDA decides what to propose. A favorable committee vote can influence that decision, but it does not control it.
- Any list change goes through rulemaking. FDA must publish the proposed action, accept comments, and issue a final rule before the 503A Bulks List formally changes.
Until then, watch the official FDA list and rulemaking record rather than pharmacy marketing or social posts claiming the peptides have been approved.
PeptideWiki previewed the seven-peptide meeting in April. The July result is a genuine shift from where the process stood then. It gives six peptides a favorable recommendation after FDA staff argued against every one of them.
The accurate headline is still narrower than "FDA clears peptides." Six advanced. One failed. None is approved, and the final regulatory decision still belongs to FDA.
Frequently Asked Questions
Is BPC-157 FDA approved now?
No. The committee recommended BPC-157 for the 503A compounding list, which is a different thing from drug approval. BPC-157 has never been approved by FDA, and this vote did not change that.
Is TB-500 legal to buy after this vote?
Nothing about how TB-500 is sold changed on July 23. The vote was a nonbinding recommendation about whether a licensed pharmacist or physician may use the bulk ingredient in patient-specific compounding. It did not create a retail pathway, and products sold for research use are not approved for human use.
What is the 503A Bulks List?
It is the federal list of bulk ingredients that pharmacists and physicians may use when compounding a customized medication for an individual patient. Compounding means preparing that medication to order rather than dispensing a mass-manufactured product. Substances reach the list through formal rulemaking, not through a committee vote.
Which peptides did the committee recommend?
BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon received favorable recommendations. Emideltide, also called DSIP, did not.
Why was Emideltide rejected?
It was the closest vote of the meeting, failing 6 to 7. FDA's review cited missing or limited safety information for the proposed routes of administration, alongside the same impurity and immune-reaction concerns raised for the other six substances.
Did FDA agree with its own advisory committee?
Not going in. FDA's briefing document proposed that neither chemical form of any of the seven peptides be included, meaning all 14 forms. The committee went the other way on six substances. Advisory committees are advisory: FDA generally follows them but is not required to.
When will FDA make a final decision?
There is no announced date. Any change to the list requires notice-and-comment rulemaking, in which the agency publishes a proposed rule, collects public comments, and then issues a final rule. That process commonly takes months to years.
Can a compounding pharmacy prepare these peptides for me today?
The federal list has not changed, so the underlying legal conditions are the same as they were before the meeting. Anyone weighing a compounded peptide should be talking to a licensed prescriber about their own situation rather than reading a vote tally as permission.
References
- US Food and Drug Administration. July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting record.
- US Food and Drug Administration. PCAC voting questions, July 23-24, 2026.
- US Food and Drug Administration. PCAC briefing document introduction, July 23-24, 2026.
- US Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A.
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.
- Lawrence L, Todd S. FDA advisory panel narrowly rejects compounding of one peptide, backs two others. STAT. July 24, 2026.
- Perrone M. FDA panel narrowly backs unapproved peptide drugs. Associated Press. July 23, 2026.
- Perrone M. FDA peptides panel includes doctors with ties to industry. Associated Press. June 29, 2026.
- US Food and Drug Administration. July 23-24, 2026 PCAC final meeting roster.
- Electronic Code of Federal Regulations. 21 CFR 216.23, current 503A Bulks List.
PeptideWiki provides educational information about research peptides. This content is not medical advice. Always consult with a qualified healthcare provider before beginning any peptide protocol. See our full disclaimer for details.
